Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Sitagliptin Shows Efficacy Up to 2 Years in Type 2 Diabetes Either Alone or as Add-On Therapy: Reported at EASD By Bruce Sylvester VIENNA, Austria -- October 3, 2009 -- Patients with type 2 diabetes treated with sitagliptin, either alone or as add-on therapy to metformin, achieve substantial improvement in glycaemic control out to 2 years. “When you look at sitagliptin data from patients over 2 years, either as monotherapy or add-on to metformin, you see glycaemic benefit in both groups out to 2 years,” said presenter and investigator Debora Williams-Herman, MD, Merck Laboratories, Rahway, New Jersey. “This adds to our developing understanding of this durability of this treatment,” she said on October 1 here at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD). For analysis of sitagliptin monotherapy, researchers pooled data from 2 clinical trials evaluating glycosylated haemoglobin (Hb A1C) response over time in 147 patients with a common baseline Hb A1C. At the time of screening, patients were not using any drugs for glycaemic control. To analyse the effect of sitagliptin as add-on therapy to metformin, researchers pooled data from 2 other clinical trials totalling 852 patients with a common baseline Hb A1C. Missing data were not included in the analysis. This included patients who used rescue therapy (46% of those receiving monotherapy and 33% of those receiving combination therapy) and for patients who discontinued treatment due to lack of efficacy. Sitagliptin monotherapy decreased mean Hb A1C from 8.5% at baseline to 6.9% in 32 patients who completed 2 years of treatment. Adding sitagliptin to metformin decreased mean Hb A1C from 8.0% at baseline to 6.9% at 2 years in 347 patients. Sitagliptin was generally well tolerated over 2 years in each of the 4 trials from which data were drawn. Funding for this study was provided by Merck. [Presentation title: Long-Term Efficacy With Sitagliptin as Monotherapy or Add-On Therapy to Metformin: Improvement in Glycaemic Control Over 2 Years in Patients With Type 2 Diabetes. Abstract 754] E-mail this page to a friend or colleague! To print, use this version